Glomerulonephritis, IGA Clinical Trial
IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. Both ACEi/ARB and steroid was found to be effective in slowing the rate of disease progression, but the use of steroid was restricted because of its side effects. However, there is no evidence from RCT on the question of whether combined use of steroid with ACEi/ARB can bring more benefit to IgAN patients than ACEi/ARB alone. We therefore undertook a randomized, multicenter study to investigate the efficacy and safety profile of combined use of ACEi/ARB plus steroid compared with ACEi/ARB alone in the treatment of patients with IgAN.
IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. In the many studies on the treatment of IgAN, both ACEi/ARB and steroid was found to be effective in slowing the rate of disease progression, but the use of steroid was restricted because of its side effects, and ACEi/ARB was considered to be the first line therapy. However, there is no evidence from RCT on the question of whether combined use of steroid with ACEi/ARB can bring more benefit to IgAN patients than ACEi/ARB alone. We therefore undertook a randomized, multicenter study to investigate the efficacy and safety profile of combined use of ACEi/ARB plus steroid compared with ACEi/ARB alone in the treatment of patients with IgAN. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03841448 -
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
|
Phase 2 | |
| Recruiting |
NCT04020328 -
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
|
Phase 4 | |
| Completed |
NCT02232776 -
Efficacy and Safety of Losartan in Children With Ig A Nephropathy
|
Phase 3 | |
| Recruiting |
NCT04092491 -
Study of the IgA Repertoire During IgA Deposition Nephropathy.
|
||
| Not yet recruiting |
NCT05797051 -
Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
|
||
| Recruiting |
NCT05791162 -
Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy
|
N/A | |
| Terminated |
NCT02647255 -
Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02160132 -
A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.
|
Phase 2 | |
| Recruiting |
NCT01184599 -
A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy
|
Phase 4 | |
| Completed |
NCT00396721 -
Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy
|
Phase 2 | |
| Recruiting |
NCT01802034 -
Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
|
||
| Recruiting |
NCT05510323 -
Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD
|
Phase 3 | |
| Completed |
NCT00446251 -
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
|
Phase 2 | |
| Active, not recruiting |
NCT04663204 -
A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy
|
Phase 2 | |
| Completed |
NCT00521508 -
Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy
|
N/A | |
| Completed |
NCT00446459 -
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
|
Phase 2 |